Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).
Park I, Yoon S, Kim I, Park K, Lee S, Keam B, Park JH, Kim JY, Choi YJ, Sohn BS, Lee JL. Park I, et al. Among authors: kim jy, kim i. Cancer Res Treat. 2024 Dec 27. doi: 10.4143/crt.2024.1003. Online ahead of print. Cancer Res Treat. 2024. PMID: 39727010 Free article.
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
Lee HY, Hong JH, Byun JH, Kim HJ, Baek SK, Kim JY, Kim KH, Yun J, Kim JA, Park K, Lee HJ, Lee JL, Won YW, Kim IH, Bae WK, Park KH, Sun DS, Lee S, Lee MY, Lee GJ, Hong SH, Jung YH, An HJ. Lee HY, et al. Cancer Res Treat. 2020 Jan;52(1):277-283. doi: 10.4143/crt.2019.292. Epub 2019 Jul 12. Cancer Res Treat. 2020. PMID: 31319640 Free PMC article.
Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial.
Park K, Jeon YK, Kim JH, Choi Y, Kim JJ, Oh SB, Oh SY, Hong YJ, Huh SJ, Kim I, Shin SH. Park K, et al. Among authors: kim jj, kim i, kim jh. Medicine (Baltimore). 2023 May 19;102(20):e33638. doi: 10.1097/MD.0000000000033638. Medicine (Baltimore). 2023. PMID: 37335745 Free PMC article. Clinical Trial.
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-Analysis Based on Individual Patient-Level Data of Randomized Trials.
Hyung J, Kang M, Kim I, Kim KP, Ryoo BY, Cheon J, Ryu H, Lee JS, Kim JW, Choi IS, Park JH, Abou-Alfa GK, Kim JW, Yoo C. Hyung J, et al. Among authors: kim kp, kim i, kim jw. Cancer Res Treat. 2024 Oct 17. doi: 10.4143/crt.2024.652. Online ahead of print. Cancer Res Treat. 2024. PMID: 39438001 Free article.
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Park S, et al. J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. J Clin Oncol. 2024. PMID: 37861993 Free PMC article. Clinical Trial.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ. Kim H, et al. Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27. Cancer. 2022. PMID: 34705268 Free PMC article.
A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer.
Kim S, Kim BJ, Kim I, Kim JH, Kim HK, Ryu H, Choi DR, Hwang IG, Song H, Kwon JH, Jung JY, Han B, Zang DY. Kim S, et al. Among authors: kim hk, kim bj, kim i, kim jh. J Cancer. 2022 Feb 14;13(4):1363-1369. doi: 10.7150/jca.70385. eCollection 2022. J Cancer. 2022. PMID: 35281880 Free PMC article.
12,591 results
You have reached the last available page of results. Please see the User Guide for more information.